MarginsXMarginsX
Home › Markets › Health Care › VRDN

Viridian Therapeutics Inc. (VRDN)

VRDN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$29.80
-3.47% on the day
Market cap
$3.4B
Mid cap
Revenue · 2025
$70.8M
+23359.9% on 2024
Net income · 2025
-$342.6M
-483.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1590750/000159075026000007/0001590750-26-000007-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerVRDN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001590750
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$70.8M
Net income-$342.6M
Operating income-$363.4M
Net margin-483.6%
Operating margin-512.9%
Revenue growth+23359.9%
Cash$212.4M
Total assets$899.4M
P/E (computed)Net income was not positive
P/S (computed)47.8×

Warning signs

Cash runway
6.1 months
$172.9M cash at September 30, 2026
Share count, 1 year
+19.0%
2025-10-31 to 2026-11-02 · +115.9% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$29.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$172.9M cash; operating cash flow -$85.4M a quarter.Report 2026-09-30
Shares outstanding113,558,449 (2026-11-02); 95,442,008 a year earlier; 52,586,039 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the marketLatest 2026-05-08
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $30.0M, sold $419K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$25.8M-$101.2M-$92.8M$172.9M$121.6M$26.3M10-Q 2026-11-04
Q2 2026
2026-06-30
$284K-$127.1M-$105.3M$165.0M$113.6M$71.1M10-Q 2026-08-06
Q1 2026
2026-03-31
$141K-$104.9M-$119.7M$176.3M$36.1M$70.9M10-Q 2026-05-05
Q4 2025
2025-12-31
$132K-$120.4M-$23.8M$212.4M$34.2M$70.8M10-K 2026-02-26
Q3 2025
2025-09-30
$70.6M-$34.6M-$84.6M$169.6M$20.9M$70.8M10-Q 2026-11-04
Q2 2025
2025-06-30
$75K-$100.7M-$75.4M$117.3M$20.8M$305K10-Q 2026-08-06
Q1 2025
2025-03-31
$72K-$86.9M-$92.7M$116.2M$20.7M$302K10-Q 2026-05-05
Q4 2024
2024-12-31
$72K-$79.7M-$73.3M$99.6M$20.6M$302K10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-08
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-17

Source: SEC EDGAR submissions feed, 821 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+8.4%
1 month+69.4%
3 months+40.4%
Year to date-0.8%
1 year+8.4%
From 52-week high-8.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
VKTXViking Therapeutics Inc.$26.80-8.28%$3.4B
ARQTArcutis Biotherapeutics Inc.$27.15-3.93%$3.4B
IRONDisc Medicine Inc.$76.59-4.26%$3.5B
ELVNEnliven Therapeutics Inc.$47.62-2.42%$3.5B
PBLSParabilis Medicines Inc.$28.45+0.07%$3.5B
ACADACADIA Pharmaceuticals Inc.$18.67-0.43%$3.2B
AMLXAmylyx Pharmaceuticals Inc.$27.80-8.22%$3.6B
ABCLAbCellera Biologics Inc. Common Shares$11.12-3.22%$3.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier